Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djaf013 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Charlotte Ouimet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Equity, Ethics and Policy, McGill University School of Population and Global Health, Montreal, QC H3A 1G1, Canada. Hauptthemen laut MEDLINE: Neoplasms, Drug Approval, Clinical Trials, Phase II as Topic, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Navigating the Valley of Death, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Background
Many patients enroll in phase 1 dose expansion cohorts or phase 2 clinical trials (together referred to below as “phase 2”) seeking access to novel treatments. Little is known about the extent to which they benefit by enrolling. Herein, we use a novel metric of benefit—therapeutic proportion—to assess the probability that patients in phase 2 trials receive treatment that eventually advances to FDA (Food and Drug Administration) approval for their condition.
Methods
We randomly sampled 400 trials identified in a search of Clinicaltrials.gov for cancer phase 2 trials initiated between November 1, 2012 and November 1, 2015. We determined whether the drug/dose/indication tested in each trial advanced to FDA approval within 7.5 years. We determined whether the drug/dose/indication presented substantial clinical benefit using the ESMO-MCBS (European Society for Medical Oncology - Magnitude of Clinical Benefit Scale), or whether it received off-label recommendation in NCCN (National Comprehensive Cancer Network) guidelines.
Results
Collectively, trials in our sample enrolled 25 002 patient-participants in 608 specific treatment cohorts. A total of 4045 patients received a treatment that advanced to FDA approval (16.2%; 95% CI = 10.3 to 22.7). The therapeutic proportion increased to 19.4% (95% CI = 14.1 to 25.8) when considering NCCN off-label recommendations and decreased to 9.3% (95% CI = 4.7 to 14.6) for FDA-approved regimens considered being of substantial clinical benefit by ESMO-MCBS. Bootstrap test of mean difference showed no statistical difference in proportions based on drug class, trial phase, or sponsorship.
Conclusion
One in 6 patients in phase 2 clinical trials receives treatments that are eventually approved. This represents a higher therapeutic value than phase 1 trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Equity, Ethics and Policy, McGill University School of Population and Global Health, Montreal, QC H3A 1G1, Canada.
- Department of Oncology, Thunder Bay Regional Health Sciences Centre and Northern Ontario School of Medicine University, Thunder Bay, ON P7B 6V4, Canada.
ORCID-Profile: Charlotte Ouimet, Bianca Fodor, Joseph C Del Paggio, Jonathan Kimmelman
Förderung
- CIHR
- Navigating the Valley of Death
- Canadian Institutes of Health Research
Zitieren
APA
Ouimet, C., Fodor, B., Del Paggio, J. C., & Kimmelman, J. (2025). Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf013
Vancouver
Ouimet C, Fodor B, Del Paggio JC, Kimmelman J. Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf013
BibTeX
@article{Ouimet2025,
author = {Ouimet, Charlotte and Fodor, Bianca and Del Paggio, Joseph C and Kimmelman, Jonathan},
title = {Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djaf013}
}
EUVIMED